Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients

American Journal of Transplantation

Volumn 12, Issue 8, 2012, Pages 2172-2180

  Weseslindtner, L ^a   Kerschner, H ^a   Steinacher, D ^a   Nachbagauer, R ^a   Kundi, M ^a   Jaksch, P ^a   Simon, B ^a   Hatos Agyi, L ^a   Scheed, A ^a   Klepetko, W ^a   Puchhammer Stockl E ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD8; CMV; DNAemia; HCMV; human cytomegalovirus; lung transplant recipients; QuantiFERON; response; T cell

Indexed keywords

GAMMA INTERFERON; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN CYTOMEGALOVIRUS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; DNA, VIRAL; HUMANS; LUNG TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 84864455451     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04076.x     Document Type: Article

References (37)

1. Humar A, Snydman D,. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S78-S86.
2. Humar A, Michaels M,. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
3. Shah PD, McDyer JF,. Viral infections in lung transplant recipients. Semin Respir Crit Care Med 2010; 31: 243-254.
4. Snydman DR, Limaye AP, Potena L, Zamora MR,. Update and review: State-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43 (Suppl 3): S1-S17.
5. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
6. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
7. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD,. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
8. Levitsky J, Freifeld AG, Puumala S, et al,. Cytomegalovirus viremia in solid organ transplantation: Does the initial viral load correlate with risk factors and outcomes? Clin Transplant 2008; 22: 222-228.
9. Humar A, Gregson D, Caliendo AM, et al,. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311.
10. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC,. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75: 2064-2068.
11. Kerschner H, Jaksch P, Karigl G, Popow-Kraupp T, Klepetko W, Puchhammer-Stockl E,. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation 2009; 87: 1720-1726.
12. Belperio JA, Weigt SS, Fishbein MC, Lynch JP, 3rd,. Chronic lung allograft rejection: Mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108-121.
13. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM,. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.
14. Gandhi MK, Khanna R,. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725-738.
15. Lidehall AK, Sund F, Lundberg T, Eriksson BM, Totterman TH, Korsgren O,. T cell control of primary and latent cytomegalovirus infections in healthy subjects. J Clin Immunol 2005; 25: 473-481.
16. Shlobin OA, West EE, Lechtzin N, et al,. Persistent cytomegalovirus- specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176: 2625-2634.
17. Pipeling MR, West EE, Osborne CM, et al,. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol 2008; 181: 546-556.
18. Westall G, Kotsimbos T, Brooks A,. CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation. Am J Transplant 2006; 6: 577-584.
19. Westall GP, Mifsud NA, Kotsimbos T,. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8: 1749-1754.
20. Sester U, Gartner BC, Wilkens H, et al,. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483-1489.
21. Bunde T, Kirchner A, Hoffmeister B, et al,. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031-1036.
22. Kumar D, Chernenko S, Moussa G, et al,. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222.
23. Pipeling MR, John ER, Orens JB, Lechtzin N, McDyer JF,. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis 2011; 204: 1663-1671.
24. Gerna G, Lilleri D, Chiesa A, et al,. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11: 2453-2471.
25. Giulieri S, Manuel O,. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011; 11: 17-25.
26. Walker S, Fazou C, Crough T, et al,. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007; 9: 165-170.
27. Lisboa LF, Asberg A, Kumar D, et al,. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011; 91: 231-236.
28. Gerna G, Lilleri D, Fornara C, et al,. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 2356-2364.
29. Elkington R, Walker S, Crough T, et al,. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226-5240.
30. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G,. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007; 7: 1997-2005.
31. Snyder LD, Medinas R, Chan C, et al,. Polyfunctional cytomegalovirus- specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant 2011; 11: 553-560.
32. Widmann T, Sester U, Gartner BC, et al,. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008; 3: e3634.
33. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ,. Primary immune responses to human CMV: A critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101: 2686-2692.
34. Danziger-Isakov L, Heeger PS,. Clinical utility of measuring T-cell immunity to CMV in transplant recipients. Am J Transplant 2009; 9: 987-988.
35. Egli A, Binet I, Binggeli S, et al,. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
36. Pignatelli S, Dal Monte P, Rossini G, Landini MP,. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 2004; 14: 383-410.
37. Puchhammer-Stockl E, Gorzer I,. Cytomegalovirus and Epstein-Barr virus subtypes-The search for clinical significance. J Clin Virol 2006; 36: 239-248.